. Author manuscript; available in PMC: 2024 Dec 13.

Published before final editing as: Dev Med Child Neurol. 2024 Dec 4:10.1111/dmcn.16199. doi: 10.1111/dmcn.16199

Table 4. Modelled assessment on secondary outcome measure (interferon (IFN) alpha protein) according to treatment arm.

Comparison (vs no treatment)	Mean difference (active vs no treatment)	98.33% CI Lower	98.33% CI Upper	p-value
ABC at 3 weeks	1817	-3621	7255	0.51
ABC at 6 weeks	-1122	-6601	4358	0.69
3TC at 3 weeks	46	-5377	5469	0.99
3TC at 6 weeks	-568	-6230	5095	0.84
ABC+3TC+AZT at 3 weeks	-1580	-7906	4747	0.62
ABC+3TC+AZT at 6 weeks	8217	1724	14709	0.01

ABC = abacavir; 3TC = lamivudine; AZT = zidovudine